AnaptysBio (ANAB) Competitors $21.11 -1.42 (-6.32%) Closing price 03:59 PM EasternExtended Trading$21.08 -0.02 (-0.10%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANAB vs. AGIO, IDYA, IBRX, HRMY, RXRX, OCUL, IRON, CGON, BLTE, and MESOShould you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), ImmunityBio (IBRX), Harmony Biosciences (HRMY), Recursion Pharmaceuticals (RXRX), Ocular Therapeutix (OCUL), Disc Medicine (IRON), CG Oncology (CGON), Belite Bio (BLTE), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. AnaptysBio vs. Its Competitors Agios Pharmaceuticals IDEAYA Biosciences ImmunityBio Harmony Biosciences Recursion Pharmaceuticals Ocular Therapeutix Disc Medicine CG Oncology Belite Bio Mesoblast AnaptysBio (NASDAQ:ANAB) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends. Do analysts rate ANAB or AGIO? AnaptysBio presently has a consensus price target of $46.13, suggesting a potential upside of 118.54%. Agios Pharmaceuticals has a consensus price target of $56.00, suggesting a potential upside of 54.75%. Given AnaptysBio's stronger consensus rating and higher probable upside, equities analysts plainly believe AnaptysBio is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is ANAB or AGIO more profitable? Agios Pharmaceuticals has a net margin of 1,590.42% compared to AnaptysBio's net margin of -107.66%. Agios Pharmaceuticals' return on equity of -3.49% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-107.66% -366.98% -30.58% Agios Pharmaceuticals 1,590.42%-3.49%-3.23% Which has stronger valuation and earnings, ANAB or AGIO? Agios Pharmaceuticals has lower revenue, but higher earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$91.28M6.47-$145.23M-$4.48-4.71Agios Pharmaceuticals$36.50M57.60$673.72M$11.003.29 Does the media prefer ANAB or AGIO? In the previous week, Agios Pharmaceuticals had 10 more articles in the media than AnaptysBio. MarketBeat recorded 16 mentions for Agios Pharmaceuticals and 6 mentions for AnaptysBio. Agios Pharmaceuticals' average media sentiment score of 1.59 beat AnaptysBio's score of 1.39 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility and risk, ANAB or AGIO? AnaptysBio has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. SummaryAgios Pharmaceuticals beats AnaptysBio on 10 of the 14 factors compared between the two stocks. Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANAB vs. The Competition Export to ExcelMetricAnaptysBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$590.97M$3.12B$5.76B$9.90BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-4.7121.0283.0226.61Price / Sales6.47379.66502.90163.15Price / CashN/A43.5325.7028.92Price / Book-13.198.1110.796.52Net Income-$145.23M-$53.35M$3.29B$266.21M7 Day Performance4.85%0.01%0.13%-0.77%1 Month Performance-12.89%7.04%7.22%3.84%1 Year Performance-43.16%11.96%50.16%24.37% AnaptysBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANABAnaptysBio2.4318 of 5 stars$21.11-6.3%$46.13+118.5%-37.6%$590.97M$91.28M-4.71100News CoveragePositive NewsAGIOAgios Pharmaceuticals4.3801 of 5 stars$37.26-4.0%$56.33+51.2%-9.2%$2.25B$36.50M3.39390News CoveragePositive NewsAnalyst ForecastOptions VolumeGap DownIDYAIDEAYA Biosciences4.4166 of 5 stars$24.71-1.6%$48.09+94.6%-32.4%$2.20B$7M-6.5280Trending NewsAnalyst ForecastAnalyst RevisionIBRXImmunityBio2.4978 of 5 stars$2.25-2.6%$10.75+377.8%-35.9%$2.18B$14.74M-4.69590HRMYHarmony Biosciences4.2992 of 5 stars$37.42-1.2%$51.00+36.3%+3.2%$2.18B$714.73M12.07200News CoveragePositive NewsRXRXRecursion Pharmaceuticals2.2937 of 5 stars$4.83-2.2%$7.00+44.9%-23.7%$2.14B$58.84M-2.71400OCULOcular Therapeutix3.4363 of 5 stars$11.87-3.5%$17.20+44.9%+55.0%$2.14B$63.72M-9.27230IRONDisc Medicine3.3174 of 5 stars$59.41-1.6%$98.30+65.5%+24.1%$2.10BN/A-13.2930Positive NewsCGONCG Oncology3.04 of 5 stars$25.42-5.6%$55.27+117.4%-18.9%$2.05B$1.14M-14.3661News CoveragePositive NewsAnalyst UpgradeBLTEBelite Bio2.2835 of 5 stars$63.62-1.2%$96.67+51.9%+31.2%$2.05BN/A-41.0510MESOMesoblast2.2014 of 5 stars$15.71-0.6%$18.00+14.6%+85.3%$2.02B$5.90M0.0080News Coverage Related Companies and Tools Related Companies Agios Pharmaceuticals Competitors IDEAYA Biosciences Competitors ImmunityBio Competitors Harmony Biosciences Competitors Recursion Pharmaceuticals Competitors Ocular Therapeutix Competitors Disc Medicine Competitors CG Oncology Competitors Belite Bio Competitors Mesoblast Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANAB) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
